Evelo Biosciences, Inc.
Formerly Evelo Therapeutics, Inc., VL28, Inc.
Total raised
$132 M
2 rounds on record
Latest round
$82 M
Feb 2018
First round on record
Jan 2017
Today
Private
No later event on record
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Evelo Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2018).
SEC Form D · Mar 2018
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2018
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
13 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alexandria Venture Investments, LLC | Venture capital | not stated | not stated | Held Series A-3, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship VentureLabs IV, LLC | Venture capital | not stated | not stated | Held Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship VentureLabs V LLC | Venture capital | not stated | not stated | Held Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Fund IV General Partner LLC | Venture capital | not stated | not stated | Held Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Fund IV, L.P. | Venture capital | not stated | not stated | Held Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Fund IV-Rx, L.P. | Venture capital | not stated | not stated | Held Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Fund V General Partner LLC | Venture capital | not stated | not stated | Held Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Fund V, L.P. | Venture capital | not stated | not stated | Held Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Opportunities Fund I General Partner LLC | Venture capital | not stated | not stated | Held Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship Ventures Opportunities Fund I, L.P. | Venture capital | not stated | not stated | Held Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Flagship V VentureLabs Rx Fund, L.P. | Venture capital | not stated | not stated | Held Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Nutritional Health Disruptive Innovation Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
| Nutritional Health Side Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A, A-1, A-2, A-3, B and C preferred stock, 10% owner (Form 3, 2018) | SEC Form 3 |
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Balkrishan (Simba) B. Gill, Ph.D. | Executive officer | Mar 2018 |
| Duncan P. McHale | Executive officer | Mar 2018 |
| Jennifer P. Glennon | Executive officer | Mar 2018 |
| Mark P. Bodmer, Ph.D. | Executive officer | Mar 2018 |
| William P. DeVaul | Executive officer | Mar 2018 |
| Balkrishan (Simba) A. Gill, Ph.D. | Executive officer | Feb 2018 |
| Derek P. Adams | Executive officer | Jan 2017 |
| Jackie P. Papkoff | Executive officer | Jan 2017 |
| Balkrishan (Simba) B. Gill, Ph.D. | Director | Mar 2018 |
| David P. Perry | Director | Mar 2018 |
| David R. Epstein | Director | Mar 2018 |
| Lord Ara P. Darzi | Director | Mar 2018 |
| Noubar B. Afeyan, Ph.D. | Director | Mar 2018 |
| Theodose B. Melas-Kyriazi | Director | Mar 2018 |
| Balkrishan (Simba) A. Gill, Ph.D. | Director | Feb 2018 |
| David A. Berry, M.D., Ph.D. | Director | Feb 2018 |
| Theodose A. Melas-Kyriazi | Director | Feb 2018 |
| Mark A. Pruzanski | Director | Jan 2017 |